Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALECTIN THERAPEUTICS INC.

(GALT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/15/2021 | 07:51am EST

Galectin Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 8.52 million compared to USD 5.94 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.1 a year ago. For the nine months, net loss was USD 23.31 million compared to USD 15.61 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.28 a year ago.


© S&P Capital IQ 2021
All news about GALECTIN THERAPEUTICS INC.
01/06Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
AQ
2021Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chair..
AQ
2021GALECTIN THERAPEUTICS : Announces Closing of $10 Million in Debt Financing from Its Chairm..
PU
2021GALECTIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
2021Galectin Therapeutics Inc. announced that it has received $20 million in funding
CI
2021Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial an..
AQ
2021GALECTIN THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021GALECTIN THERAPEUTICS : Thanks Kevin - Form 8-K
PU
2021GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021GALECTIN THERAPEUTICS : Reports Financial Results for the Quarter Ended September 30, 2021..
PU
More news
Analyst Recommendations on GALECTIN THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -34,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,25x
Yield 2021 -
Capitalization 114 M 114 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 70,5%
Chart GALECTIN THERAPEUTICS INC.
Duration : Period :
Galectin Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALECTIN THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,92 $
Average target price 14,00 $
Spread / Average Target 629%
EPS Revisions
Managers and Directors
Joel Lewis President, Chief Executive Officer & Director
Jack W. Callicutt Chief Financial Officer & Secretary
Richard E. Uihlein Chairman
Pol F. Boudes Chief Medical Officer
Ezra R. lowe Executive Director-Clinical
Sector and Competitors
1st jan.Capi. (M$)
GALECTIN THERAPEUTICS INC.-7.25%114
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508